PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

By S. Patel, Razelle Kurzrock. Molecular Cancer Therapeutics, 2015

1,996 citations recorded by the source corpus.

Subfields: Immunology, Oncology

View Paper: https://www.semanticscholar.org/paper/69b0895b1e610335f1af9ef9bf1b326877e0a1d9

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Immunology

1. E. Buchbinder
2. L. Emens
3. Anupam M. Desai
4. Razelle Kurzrock
5. S. Patel

In Oncology

1. Vincent A. Miller
2. E. Buchbinder
3. L. Emens
4. Anupam M. Desai
5. Razelle Kurzrock
6. S. Patel

Citations in the corpus

• Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling (2017, background): “Selection of agents could be based on analysis of pre-treatment tissue samples, including mutation testing and PD-L1 expression (19,20).”
• Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study (2017, methodology): “To date, the use of PD-L1 as a predictive biomarker for MBC remains controversial given the use of different PD-L1 antibodies and detection assays, various PD-L1 expression cutoffs, and non-standardized test designs [30, 31].”
• Integrative Clinical Genomics of Metastatic Cancer (2017, neutral): “However, immune biomarkers need to characterize a complex disease state comprising the tumor genotype (e.g., mutational burden), phenotype (e.g., PD-L1 expression), and host response (e.g., presence of CD8+ T-cells).”
• Antitumor Activity and Safety of Pembrolizumab in Patients with Advanced Recurrent Ovarian Cancer: Results from the Phase 2 KEYNOTE-100 Study. (2019, background): “It is important to note that across studies of different checkpoint inhibitors, PD-L1 assays use different antibodies with a variety of cut points, each with unique and different thresholds for defining PD-L1 positivity [17, 18].”
• PD‐L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD‐L1 IHC Assay Comparison Project (2017, background): “The study also did not address how differences in specimen type or preanalytical factors across laboratories (such as fixatives and tissue processing methods) may affect the performance of the assays.(34) An ongoing phase 2 of this study includes a much larger set of tumors with comparisons of large”